PD-1 x CTLA-4 drugs for Non-Small Cell Lung Cancer
4 tracked PD-1 x CTLA-4 drugs in the Non-Small Cell Lung Cancer race. The class explanation lives on the PD-1 x CTLA-4 page; the full indication pipeline across every mechanism is on the Non-Small Cell Lung Cancer page.
2 Phase 31 Phase 21 Phase 1
Head-to-head evidence: AI-061 vs Volrustomig · Danvilostomig vs Volrustomig · Iparomlimab and tuvonralimab vs Volrustomig